Chun A H, Carrigan P J, Hoffman D J, Kershner R P, Stuart J D
Clin Pharmacol Ther. 1977 Sep;22(3):329-35. doi: 10.1002/cpt1977223329.
The effect of a magnesia and alumina antacid suspension on the absorption of clorazepate dipotassium was studied in 15 normal healthy adult subjects who ingested a 15-mg dose of clorazepate alone or with single or multiple doses of antacid. The results of this three-period randomized complete crossover study showed a trend of initially slower absorption and lower peak nordiazepam plasma levels when administered with the antacid suspension. However, there were no significant differences among treatments in the extent of absorption as measured by the area under the plasma level-time curves. Clorazepate plasma levels were of relatively short duration and similar for all treatments. The urinary excretion pattern was likewise comparable with conjugated oxazepam, the major species measured. Plasma elimination half-lives of nordiazepam and clorazepate were not affected by the antacid treatments.
在15名正常健康成年受试者中研究了氧化镁和氧化铝抗酸混悬液对二钾氯氮䓬吸收的影响,这些受试者单独摄入15毫克二钾氯氮䓬,或同时摄入单剂量或多剂量抗酸剂。这项三阶段随机完全交叉研究的结果显示,与抗酸混悬液一起给药时,最初吸收较慢且去甲地西泮血浆峰值水平较低的趋势。然而,通过血浆水平-时间曲线下面积测量的吸收程度在各治疗组之间没有显著差异。氯氮䓬血浆水平持续时间相对较短,且所有治疗组相似。尿排泄模式与主要测量的结合型奥沙西泮同样具有可比性。去甲地西泮和氯氮䓬的血浆消除半衰期不受抗酸剂治疗的影响。